Loading...
XSTOIMMU
Market cap40mUSD
Dec 23, Last price  
8.80SEK
1D
4.02%
1Q
3.53%
Jan 2017
-61.73%
IPO
27.97%
Name

Mendus AB (publ)

Chart & Performance

D1W1MN
XSTO:IMMU chart
P/E
—
P/S
15.56
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-16.15%
Rev. gr., 5y
%
Revenues
28m
+851.15%
005,000000000016,670,00006,0002,995,00028,487,000
Net income
-102m
L-25.82%
-2,287,294-2,670,303-2,629,325-6,887,974-16,175,036-35,614,623-43,922,885-73,587,834-80,337,643-97,860,000-135,708,000-92,469,000-136,694,000-136,991,000-101,619,000
CFO
-163m
L+48.87%
-1,666,198-3,233,502-7,146,028-9,280,851-40,102,127-40,228,602-33,738,195-46,446,815-104,670,000-145,808,000-56,626,000-138,033,000-109,331,000-162,761,000
Earnings
Feb 13, 2025

Profile

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
URL
https://mendus.com/
IPO date
Apr 22, 2013
Employees
30
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑062015‑06
Income
Revenues
28,487
851.15%
2,995
49,816.67%
6
 
Cost of revenue
129,704
140,773
131,137
Unusual Expense (Income)
NOPBT
(101,217)
(137,778)
(131,131)
NOPBT Margin
Operating Taxes
(1,794)
3,284
Tax Rate
NOPAT
(101,217)
(135,984)
(134,415)
Net income
(101,619)
-25.82%
(136,991)
0.22%
(136,694)
47.83%
Dividends
Dividend yield
Proceeds from repurchase of equity
321,793
141,242
BB yield
Debt
Debt current
2,523
31,611
309
Long-term debt
45,603
72,670
36,975
Deferred revenue
Other long-term liabilities
(1,000)
(36,666)
Net debt
(72,656)
61,813
(118,872)
Cash flow
Cash from operating activities
(162,761)
(109,331)
(138,033)
CAPEX
(1,823)
(12,097)
(1,361)
Cash from investing activities
(442)
(12,324)
(1,361)
Cash from financing activities
242,097
8,194
127,029
FCF
(138,025)
(170,980)
(136,625)
Balance
Cash
120,782
41,850
155,313
Long term investments
618
843
Excess cash
119,358
42,318
156,156
Stockholders' equity
(690,031)
(616,015)
(473,592)
Invested Capital
1,419,246
1,206,645
1,165,782
ROIC
ROCE
EV
Common stock shares outstanding
23,128
216,488
199,750
Price
Market cap
EV
EBITDA
(94,914)
(132,930)
(129,280)
EV/EBITDA
Interest
3,115
5,264
3,284
Interest/NOPBT